KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology's Accumulated Depreciation history spans 6 years, with the latest figure at $26.2 million for Q1 2023.

  • On a quarterly basis, Accumulated Depreciation rose 65.06% to $26.2 million in Q1 2023 year-over-year; TTM through Mar 2023 was $26.2 million, a 65.06% increase, with the full-year FY2022 number at $20.7 million, up 43.13% from a year prior.
  • Accumulated Depreciation hit $26.2 million in Q1 2023 for Vir Biotechnology, up from $20.7 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for VIR hit a ceiling of $26.2 million in Q1 2023 and a floor of $4.2 million in Q3 2019.
  • Historically, Accumulated Depreciation has averaged $12.5 million across 5 years, with a median of $11.8 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation: soared 181.59% in 2019 and later soared 43.13% in 2022.
  • Tracing VIR's Accumulated Depreciation over 5 years: stood at $4.8 million in 2019, then skyrocketed by 91.06% to $9.2 million in 2020, then soared by 56.98% to $14.5 million in 2021, then skyrocketed by 43.13% to $20.7 million in 2022, then increased by 26.54% to $26.2 million in 2023.
  • Business Quant data shows Accumulated Depreciation for VIR at $26.2 million in Q1 2023, $20.7 million in Q4 2022, and $18.9 million in Q3 2022.